How does the current valuation (P/E, EV/EBITDA) compare to key competitors in the medical device sector after this release?
Short answer:
The press‑release you shared does not contain any of the valuation figures (‑ price‑to‑earnings (P/E) or enterprise‑value‑to‑EBITDA (EV/EBITDA) – nor the underlying earnings, EBITDA, or market‑capitalisation numbers that are needed to calculate them. Consequently, we cannot provide a concrete “after‑release” comparison of Coloplast’s (COLO) valuation to its peers based solely on the information supplied.
Below is a step‑by‑step framework you can use to determine the current valuation metrics for Coloplast and to compare them with the most relevant peers in the medical‑device sector once the 9‑month 2024/25 results have been published.
1. Gather the needed data
| Metric | Where to get it | Typical source |
|---|---|---|
| Share price (as of the day after the release) | Real‑time market data (e.g., Bloomberg, Reuters, Yahoo! Finance) | Exchange or financial data terminal |
| Shares outstanding | Coloplast’s Q3‑2024/25 earnings release / latest annual report | Company IR site |
| Net income (or earnings) for the period | 9‑month 2024/25 results (likely disclosed in the earnings release) | Coloplast press release / SEC/EFSA filing |
| EBITDA (or Adjusted EBITDA) | Same earnings release – usually presented as “EBITDA” or “EBITDA (adjusted)” | Coloplast IR |
| Cash and cash equivalents, debt, minority interest | Balance‑sheet line items in the same release | |
| Enterprise value (EV) | EV = Market Capitalisation + Net Debt (Debt – Cash) + Minority Interest – Cash & Cash Equivalents (if any) | Compute from the above numbers |
| Earnings per share (EPS) | Net income / Shares outstanding | |
| P/E ratio | Current share price ÷ EPS (annualised) or price ÷ trailing 12‑month earnings | |
| EV/EBITDA | Enterprise value ÷ EBITDA (annualised) |
Note: The “annualised” version is usually used for EV/EBITDA (i.e., the 9‑month figure multiplied by 4/3 to extrapolate a full‑year figure). Some analysts prefer a “trailing twelve‑month” (TTM) approach if the Q3 results are not yet adjusted for seasonality.
2. Identify the most relevant peers
Coloplast operates mainly in advanced wound care, continence & stoma care, and urology (catheters, wound dressings, etc.). Typical peers that are often used for benchmarking in the “medical‑device – specialty products” space include:
| Peer (Ticker) | Primary focus | Market‑cap (approx., 2025) |
|---|---|---|
| Medtronic (MDT) | Broad medical‑device portfolio (including wound care) | ~US$150‑200 bn |
| Abbott Laboratories (ABT) | Broad health‑care, includes medical‑device division | ~US$200 bn |
| Becton Dickinson (BDX) | Medical supplies, wound care, diagnostics | ~US$70‑80 bn |
| Stryker (SYK) | Orthopedics, surgical equipment | ~US 100 bn+ |
| ConvaTec (COT) – (if still listed) | Wound & continence care (direct competitor) | ~US$5‑8 bn |
| Halyard Health (part of 3M, but often benchmarked) | Wound care & infection control | N/A |
How to decide the peer group
- Product overlap (wound‑care, stoma, continence) → ConvaTec, Medtronic’s wound‑care segment, or even Smith & Nephew (SNP).
- Geographic footprint (global presence, European focus) → B. Dickinson, Haleon (though more pharma).
- Size and liquidity → Choose peers with market capitalisation within a factor of 5‑10 of Coloplast for a meaningful multiple comparison.
3. Calculate the ratios
Calculate P/E
- P = Closing share price (e.g., 10 EUR)
- E = FY‑2024/25 EPS (e.g., 1.2 EUR) → P/E = 10 / 1.2 = 8.3×
- For a fair comparison, use trailing‑12‑month EPS (or annualised Q9‑month EPS).
- P = Closing share price (e.g., 10 EUR)
Calculate EV/EBITDA
- EV = (Share price × shares outstanding) + net debt (e.g., 2 bn EUR)
- EBITDA = Q9‑month EBITDA (e.g., 400 m EUR) → annualised ≈ 400 m × 4/3 = 533 m EUR
- EV/EBITDA = (Market cap + net debt) / 533 m ≈ 7‑9×
- EV = (Share price × shares outstanding) + net debt (e.g., 2 bn EUR)
Repeat the same calculation for each peer using their latest published figures (often found in the same quarterly release or the latest 10‑Q/annual report).
Important – Use the same basis for every company: either trailing (last 12 months) or forward (projected FY) – never mix the two.
4. Interpreting the results
| Ratio | Interpretation (relative to peers) |
|---|---|
| P/E lower than peers | The market may be discounting Coloplast’s growth prospects, or the company may be perceived as higher risk/ lower growth. |
| P/E higher | Market expects higher future growth or superior margins relative to peers. |
| EV/EBITDA lower | Potentially undervalued on a cash‑flow basis; may indicate cheaper acquisition price relative to operating earnings. |
| EV/EBITDA higher | Market may be paying a premium for growth, brand strength, or better cash‑flow stability. |
Typical ranges in the medical‑device sector (2024‑2025):
- P/E: 12‑30× (higher for growth‑oriented biotech/med‑device; lower for mature, low‑growth companies).
- EV/EBITDA: 9‑15× (again, higher for high‑growth, lower for mature or debt‑heavy firms).
If Coloplast’s P/E comes out ~7‑9× and its EV/EBITDA ~7‑9×, that would place it below the sector average, indicating a potentially undervalued position (if fundamentals support it). Conversely, if the figures are >20× and >12× respectively, the market may be pricing in strong growth or a strategic premium (e.g., upcoming product launches, acquisitions, or superior margin expansion).
5. Practical steps to obtain the numbers today
- Wait for the 9‑month 2024/25 results (published around 07:30 CEST on 19 August 2025).
- Download the press release and the accompanying slide deck (the slides usually contain a “Key financials” table with revenue, EBIT, EBITDA, net income, EPS).
- Pull the closing price on 19 Aug 2025 (or 20 Aug 2025 if you want the first full‑day after the release).
- Use a financial data terminal (Bloomberg, Refinitiv, FactSet) to pull the same‑day market cap and net‑debt for Coloplast and each competitor.
- Compute the ratios and put them into a table for comparison.
Bottom‑line answer
Based solely on the conference‑call invitation you provided, there is insufficient data to calculate the actual post‑release P/E or EV/EBITDA for Coloplast (COLO) or to compare it to peers. To produce a meaningful comparison you’ll need the actual earnings and EBITDA figures that will be disclosed in the 9‑month 2024/25 earnings release, plus current market prices and debt data. Once you have those numbers, the steps and guidance above will enable you to compute the ratios and assess whether Coloplast’s valuation is higher, lower, or in line with its key competitors in the medical‑device sector.